Danaher Corporation $DHR Shares Bought by Canoe Financial LP

Canoe Financial LP increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 43.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 800,124 shares of the conglomerate's stock after purchasing an additional 241,910 shares during the period. Danaher makes up approximately 2.1% of Canoe Financial LP's portfolio, making the stock its 17th biggest holding. Canoe Financial LP owned approximately 0.11% of Danaher worth $169,434,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Danaher during the second quarter valued at approximately $10,492,520,000. Wellington Management Group LLP increased its holdings in shares of Danaher by 10.4% in the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock worth $3,108,031,000 after buying an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC bought a new position in shares of Danaher in the 2nd quarter worth $1,456,317,000. Generation Investment Management LLP bought a new position in shares of Danaher in the 2nd quarter worth $1,287,949,000. Finally, Bank of America Corp DE purchased a new stake in shares of Danaher during the 2nd quarter valued at $993,846,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price objective on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a report on Wednesday, July 22nd. Wall Street Zen cut Danaher from a "buy" rating to a "hold" rating in a research note on Sunday. The Goldman Sachs Group increased their target price on Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a research note on Monday, September 21st. Barclays raised their price target on Danaher from $230.00 to $255.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Finally, Weiss Ratings raised Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $235.41.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Adjusted EPS beat expectations: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus and up from $1.89 a year earlier. Profitability was supported by strength in the Biotechnology segment. Danaher Reports Third Quarter 2026 Results
• Positive Sentiment: Full-year outlook raised: Management increased its 2026 adjusted EPS guidance to $8.57-$8.62, above the prior outlook and analyst expectations. The improved forecast signals confidence that customer demand and operating trends are continuing to recover. Danaher: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Biotechnology momentum improved: Biotechnology orders grew at a mid-teens rate in the quarter, while management described improving trends across end markets. Danaher also said it has the technological “building blocks” to pursue future growth from artificial intelligence in drug discovery. Danaher says it has building blocks for AI drug discovery growth
• Neutral Sentiment: Revenue was broadly on target: Third-quarter revenue rose 8.3% year over year to $6.55 billion, just below the $6.56 billion consensus. The near miss was outweighed by the earnings and guidance beats but limits the evidence of a broad-based sales acceleration. Danaher’s Q3 2026 Earnings Results
• Negative Sentiment: Mixed segment performance and leadership uncertainty remain risks: The Masimo acquisition helped offset declines in respiratory diagnostic sales, while investors continue to assess the implications of Danaher’s CEO transition. These issues could restrain the stock if weaker businesses do not stabilize. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales

Danaher Price Performance

DHR stock opened at $233.99 on Thursday. The firm has a market cap of $164.49 billion, a P/E ratio of 27.62, a P/E/G ratio of 2.82 and a beta of 0.76. The firm's fifty day moving average is $215.25 and its 200 day moving average is $196.84. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, topping the consensus estimate of $1.92 by $0.19. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. During the same period in the previous year, the firm posted $1.89 earnings per share. The firm's revenue for the quarter was up 8.3% on a year-over-year basis. Research analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher's payout ratio is currently 28.42%.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.